U.S. markets close in 6 hours 13 minutes
  • S&P 500

    4,462.95
    -8.42 (-0.19%)
     
  • Dow 30

    35,156.48
    -138.28 (-0.39%)
     
  • Nasdaq

    14,883.29
    -14.05 (-0.09%)
     
  • Russell 2000

    2,256.94
    -8.72 (-0.38%)
     
  • Crude Oil

    83.51
    +1.23 (+1.49%)
     
  • Gold

    1,767.00
    -1.30 (-0.07%)
     
  • Silver

    23.24
    -0.11 (-0.47%)
     
  • EUR/USD

    1.1608
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.6060
    +0.0570 (+3.68%)
     
  • GBP/USD

    1.3728
    +0.0051 (+0.37%)
     
  • USD/JPY

    114.2960
    +0.6190 (+0.54%)
     
  • BTC-USD

    61,387.96
    +673.77 (+1.11%)
     
  • CMC Crypto 200

    1,438.40
    -13.23 (-0.91%)
     
  • FTSE 100

    7,188.66
    -45.37 (-0.63%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report fourth quarter and full-year 2018 financial results on Thursday, March 28, 2019, before market open.

The company will not be conducting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.

Contact:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com

Media Contact:
Dan Budwick
1AB.
+1 (973) 271-6085
dan@1abmedia.com